NewAmsterdam Pharma Stock (NASDAQ:NAMS)
Previous Close
$23.60
52W Range
$14.06 - $27.29
50D Avg
$19.90
200D Avg
$20.73
Market Cap
$2.63B
Avg Vol (3M)
$855.37K
Beta
-0.03
Div Yield
-
NAMS Company Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.